← Back to patent-cliff list
ENTR-601-45
Tier C — Watch / tradeENTR-601-45
Entrada Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：RNA
Indications (approved)：Duchenne muscular dystrophy
Regional status
US
-
2024-06-01
EU
Phase II
2025-08-30
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ENTR-601-45?
Approved indications include: Duchenne muscular dystrophy.
When does the ENTR-601-45 patent expire?
No public expiry year is available for ENTR-601-45 yet; this page updates once verified.
How do I get a quote for ENTR-601-45 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30